Wuhan YZY Biopharma Co Ltd 2024 SR
The report highlights YZYBIO's commitment to developing bispecific antibody-based therapies for cancer and ophthalmologic diseases. In 2024, the company advanced its lead product M701 to Phase III clinical trials for malignant ascites and received the First Prize of the National Science and Technology Progress Award. The company achieved a 14% reduction in per capita carbon emissions and a 12% reduction in per capita electricity consumption compared to the previous year. Additionally, YZYBIO maintained a 100% coverage rate for labor contracts and social insurance while fostering a diverse workforce of 122 employees.
Company: Wuhan YZY Biopharma Co Ltd
Sector: Health Care
Country: China
Year: 2024
Type: SR
Pages: 30
Wuhan YZY Biopharma Co Ltd
ESG Report
The report highlights YZYBIO's commitment to developing bispecific antibody-based therapies for cancer and ophthalmologic diseases. In 2024, the company advanced its lead product M701 to Phase III clinical trials for malignant ascites and received the First Prize of the National Science and Technology Progress Award. The company achieved a 14% reduction in per capita carbon emissions and a 12% reduction in per capita electricity consumption compared to the previous year. Additionally, YZYBIO maintained a 100% coverage rate for labor contracts and social insurance while fostering a diverse workforce of 122 employees.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Workplace Fatalities
Employees